NASDAQ:PBYI - Puma Biotechnology Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$51.90 +0.30 (+0.58 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$51.90
Today's Range$51.15 - $52.5034
52-Week Range$50.15 - $136.90
Volume368,127 shs
Average Volume938,524 shs
Market Capitalization$1.95 billion
P/E Ratio-6.61
Dividend YieldN/A
Beta0.18

About Puma Biotechnology (NASDAQ:PBYI)

Puma Biotechnology logoPuma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Receive PBYI News and Ratings via Email

Sign-up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PBYI
CUSIPN/A
Phone424-248-6500

Debt

Debt-to-Equity Ratio0.85
Current Ratio1.91
Quick Ratio1.87

Price-To-Earnings

Trailing P/E Ratio-6.61
Forward P/E Ratio-13.55
P/E GrowthN/A

Sales & Book Value

Annual Sales$26.20 million
Price / Sales74.90
Cash FlowN/A
Price / CashN/A
Book Value$1.52 per share
Price / Book34.14

Profitability

EPS (Most Recent Fiscal Year)($7.85)
Net Income$-291,950,000.00
Net MarginsN/A
Return on Equity-314.05%
Return on Assets-141.14%

Miscellaneous

Employees318
Outstanding Shares37,810,000

Puma Biotechnology (NASDAQ:PBYI) Frequently Asked Questions

What is Puma Biotechnology's stock symbol?

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology (NASDAQ:PBYI) issued its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($1.26) by $0.61. The biopharmaceutical company had revenue of $66.50 million for the quarter, compared to analysts' expectations of $67.33 million. During the same period in the prior year, the firm posted ($1.16) EPS. View Puma Biotechnology's Earnings History.

When is Puma Biotechnology's next earnings date?

Puma Biotechnology is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Puma Biotechnology.

What price target have analysts set for PBYI?

9 Wall Street analysts have issued 12 month price targets for Puma Biotechnology's shares. Their predictions range from $68.00 to $146.00. On average, they anticipate Puma Biotechnology's share price to reach $102.2222 in the next year. View Analyst Ratings for Puma Biotechnology.

Who are some of Puma Biotechnology's key competitors?

Who are Puma Biotechnology's key executives?

Puma Biotechnology's management team includes the folowing people:
  • Mr. Alan H. Auerbach, Founder, Chairman, CEO, Pres & Sec. (Age 48)
  • Mr. Charles R. Eyler, Sr. VP of Fin. & Admin. and Treasurer (Age 70)
  • Dr. Richard P. Bryce MBChB, MRCGP, MFPM, Chief Medical & Scientific Officer (Age 61)
  • Mr. Steven Lo, Chief Commercial Officer (Age 51)
  • Mr. Douglas Hunt, Sr. VP of Regulatory Affairs, Medical Writing & Project Management

Has Puma Biotechnology been receiving favorable news coverage?

Media stories about PBYI stock have trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Puma Biotechnology earned a coverage optimism score of 0.12 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 46.80 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Puma Biotechnology's major shareholders?

Puma Biotechnology's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.28%), Point72 Asset Management L.P. (3.39%), Redmile Group LLC (2.90%), Franklin Resources Inc. (2.27%), venBio Select Advisor LLC (2.18%) and Rock Springs Capital Management LP (1.09%). Company insiders that own Puma Biotechnology stock include Adage Capital Partners Gp, LL, Alan H Auerbach, Charles R Eyler, Richard Paul Bryce and Robert Charnas. View Institutional Ownership Trends for Puma Biotechnology.

Which major investors are selling Puma Biotechnology stock?

PBYI stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, UBS Group AG, Millennium Management LLC, Eversept Partners LLC, BlackRock Inc., Sivik Global Healthcare LLC, California Public Employees Retirement System and Teacher Retirement System of Texas. Company insiders that have sold Puma Biotechnology company stock in the last year include Adage Capital Partners Gp, LL, Alan H Auerbach, Charles R Eyler and Richard Paul Bryce. View Insider Buying and Selling for Puma Biotechnology.

Which major investors are buying Puma Biotechnology stock?

PBYI stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., venBio Select Advisor LLC, Summit Trail Advisors LLC, Redmile Group LLC, BNP Paribas Arbitrage SA, PointState Capital LP, Federated Investors Inc. PA and Rock Springs Capital Management LP. View Insider Buying and Selling for Puma Biotechnology.

How do I buy shares of Puma Biotechnology?

Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Puma Biotechnology's stock price today?

One share of PBYI stock can currently be purchased for approximately $51.90.

How big of a company is Puma Biotechnology?

Puma Biotechnology has a market capitalization of $1.95 billion and generates $26.20 million in revenue each year. The biopharmaceutical company earns $-291,950,000.00 in net income (profit) each year or ($7.85) on an earnings per share basis. Puma Biotechnology employs 318 workers across the globe.

How can I contact Puma Biotechnology?

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected]


MarketBeat Community Rating for Puma Biotechnology (PBYI)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  352 (Vote Outperform)
Underperform Votes:  278 (Vote Underperform)
Total Votes:  630
MarketBeat's community ratings are surveys of what our community members think about Puma Biotechnology and other stocks. Vote "Outperform" if you believe PBYI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PBYI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Puma Biotechnology (NASDAQ:PBYI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for Puma Biotechnology in the last 12 months. Their average twelve-month price target is $102.2222, suggesting that the stock has a possible upside of 96.96%. The high price target for PBYI is $146.00 and the low price target for PBYI is $68.00. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.782.89
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $102.2222$103.1111$110.5556$130.6667
Price Target Upside: 96.96% upside60.61% upside21.62% upside26.86% upside

Puma Biotechnology (NASDAQ:PBYI) Consensus Price Target History

Price Target History for Puma Biotechnology (NASDAQ:PBYI)

Puma Biotechnology (NASDAQ:PBYI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2018Stifel NicolausLower Price TargetBuy ➝ Buy$95.00 ➝ $87.00MediumView Rating Details
5/7/2018Credit Suisse GroupSet Price TargetBuy$106.00MediumView Rating Details
4/12/2018BarclaysDowngradeOverweight ➝ Equal Weight$90.00HighView Rating Details
1/24/2018Bank of AmericaLower Price TargetBuy ➝ Buy$135.00 ➝ $115.00HighView Rating Details
1/24/2018CitigroupLower Price TargetBuy ➝ Buy$164.00 ➝ $146.00HighView Rating Details
1/24/2018Royal Bank of CanadaLower Price TargetSector Perform$77.00HighView Rating Details
1/24/2018JPMorgan Chase & Co.Lower Price TargetOverweight ➝ Buy$138.00 ➝ $91.00HighView Rating Details
1/24/2018CowenDowngradeOutperform ➝ Market Perform$123.00 ➝ $68.00HighView Rating Details
10/27/2017Leerink SwannBoost Price TargetPositive ➝ Outperform$140.00N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Puma Biotechnology (NASDAQ:PBYI) Earnings History and Estimates Chart

Earnings by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Puma Biotechnology (NASDAQ:PBYI) Earnings Estimates

2018 EPS Consensus Estimate: ($5.58)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.87)($1.87)($1.87)
Q2 20181($1.55)($1.55)($1.55)
Q3 20181($1.21)($1.21)($1.21)
Q4 20181($0.95)($0.95)($0.95)

Puma Biotechnology (NASDAQ PBYI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018($1.26)N/AView Earnings Details
5/9/2018Q1 2018($1.26)($0.65)$67.33 million$66.50 millionViewN/AView Earnings Details
3/1/2018Q4 2017($1.98)($1.71)$20.83 million$21.60 millionViewListenView Earnings Details
11/9/2017Q3 2017($2.50)($2.07)$3.78 million$6.10 millionViewN/AView Earnings Details
8/9/2017Q2 2017($1.32)($2.10)ViewN/AView Earnings Details
5/10/2017Q1 2017($2.06)($1.97)ViewN/AView Earnings Details
3/1/2017Q4($1.92)($2.04)ViewN/AView Earnings Details
11/9/2016Q3 2016($2.00)($2.02)ViewN/AView Earnings Details
8/9/2016Q2 2016($2.20)($2.05)ViewN/AView Earnings Details
5/10/2016Q1($1.99)($1.28)ViewN/AView Earnings Details
2/29/2016Q4($1.95)($1.23)ViewN/AView Earnings Details
11/9/2015Q3($1.84)($1.87)ViewN/AView Earnings Details
8/10/2015Q2($1.55)($1.13)ViewN/AView Earnings Details
5/11/2015Q1($1.25)($1.02)ViewN/AView Earnings Details
3/2/2015($1.15)($1.59)ViewN/AView Earnings Details
11/10/2014($1.27)($1.19)ViewN/AView Earnings Details
8/11/2014Q214($0.66)($1.05)ViewN/AView Earnings Details
5/12/2014($0.48)($0.67)ViewN/AView Earnings Details
3/3/2014Q413($0.49)($0.46)ViewN/AView Earnings Details
11/12/2013Q3 2013($0.46)($0.49)ViewN/AView Earnings Details
8/6/2013Q2 2013($0.44)($0.43)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.40)ViewN/AView Earnings Details
4/1/2013Q413($0.70)($0.25)ViewN/AView Earnings Details
11/14/2012Q312($1.29)ViewN/AView Earnings Details
8/14/2012Q2 2012($0.74)ViewN/AView Earnings Details
5/15/2012Q1 2012($0.59)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Puma Biotechnology (NASDAQ:PBYI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Puma Biotechnology (NASDAQ PBYI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 21.10%
Institutional Ownership Percentage: 97.95%
Insider Trading History for Puma Biotechnology (NASDAQ:PBYI)
Institutional Ownership by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Puma Biotechnology (NASDAQ PBYI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/22/2018Alan H AuerbachInsiderSell10,692$92.75$991,683.004,155,931View SEC Filing  
1/22/2018Richard Paul BryceSVPSell1,860$92.75$172,515.0025,379View SEC Filing  
12/1/2017Charles R EylerInsiderSell1,322$105.46$139,418.12View SEC Filing  
9/29/2017Richard Paul BryceSVPSell15,000$120.00$1,800,000.0042,239View SEC Filing  
9/7/2017Richard Paul BryceSVPSell15,000$100.09$1,501,350.0028,239View SEC Filing  
7/20/2017Alan H AuerbachInsiderSell13,175$94.73$1,248,067.754,170,623View SEC Filing  
7/20/2017Richard Paul BryceSVPSell1,998$94.48$188,771.0427,246View SEC Filing  
7/3/2017Richard Paul BryceSVPSell5,000$87.10$435,500.0034,237View SEC Filing  
6/12/2017Adage Capital Partners Gp, L.LMajor ShareholderSell247,260$80.32$19,859,923.20View SEC Filing  
6/5/2017Adage Capital Partners Gp, L.LMajor ShareholderSell507,128$87.84$44,546,123.52View SEC Filing  
5/26/2017Adage Capital Partners Gp, L.LMajor ShareholderSell1,235,700$75.38$93,147,066.00View SEC Filing  
2/1/2017Robert CharnasInsiderSell3,008$31.83$95,744.6428,461View SEC Filing  
1/20/2017Alan H AuerbachInsiderSell10,202$33.24$339,114.484,179,798View SEC Filing  
1/20/2017Richard Paul BryceSVPSell2,293$33.24$76,219.3229,237View SEC Filing  
7/6/2015Richard Paul BryceSVPSell3,000$110.03$330,090.00View SEC Filing  
11/8/2013Adage Capital Partners Gp Llcmajor shareholderBuy22,549$38.92$877,607.08View SEC Filing  
11/5/2013Adage Capital Partners Gp Llcmajor shareholderBuy280,700$39.60$11,115,720.00View SEC Filing  
10/9/2013Adage Capital Partners Gp Llcmajor shareholderBuy140,900$40.44$5,697,996.00View SEC Filing  
12/18/2012Adage Capital Partners Gp LlcMajor ShareholderBuy29,560$19.00$561,640.00View SEC Filing  
12/12/2012Adage Capital Partners Gp LlcMajor ShareholderBuy30,400$19.00$577,600.00View SEC Filing  
12/11/2012Adage Capital Partners Gp LlcMajor ShareholderBuy140,040$18.98$2,657,959.20View SEC Filing  
10/24/2012Thomas MalleyDirectorBuy10,000$16.00$160,000.00View SEC Filing  
10/18/2012Adage Capital Partners Gp LlcMajor ShareholderBuy610,000$16.00$9,760,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Puma Biotechnology (NASDAQ PBYI) News Headlines

Source:
DateHeadline
Puma Biotechnology (PBYI) Receives Consensus Rating of "Buy" from BrokeragesPuma Biotechnology (PBYI) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 17 at 12:43 PM
Edited Transcript of PBYI earnings conference call or presentation 9-May-18 8:30pm GMTEdited Transcript of PBYI earnings conference call or presentation 9-May-18 8:30pm GMT
finance.yahoo.com - May 17 at 9:08 AM
Todays Research Reports on Trending Tickers: Puma Biotechnology and Amicus TherapeuticsToday's Research Reports on Trending Tickers: Puma Biotechnology and Amicus Therapeutics
finance.yahoo.com - May 16 at 9:08 AM
$47.45 Million in Sales Expected for Puma Biotechnology (PBYI) This Quarter$47.45 Million in Sales Expected for Puma Biotechnology (PBYI) This Quarter
www.americanbankingnews.com - May 15 at 4:20 AM
-$1.18 EPS Expected for Puma Biotechnology (PBYI) This Quarter-$1.18 EPS Expected for Puma Biotechnology (PBYI) This Quarter
www.americanbankingnews.com - May 13 at 8:56 AM
Stifel Nicolaus Trims Puma Biotechnology (PBYI) Target Price to $87.00Stifel Nicolaus Trims Puma Biotechnology (PBYI) Target Price to $87.00
www.americanbankingnews.com - May 11 at 5:49 PM
Puma Biotechnology (PBYI) PT Lowered to $87 at StifelPuma Biotechnology (PBYI) PT Lowered to $87 at Stifel
www.streetinsider.com - May 11 at 9:37 AM
Today’s Research Reports on Stocks to Watch: Puma Biotechnology and NeovascToday’s Research Reports on Stocks to Watch: Puma Biotechnology and Neovasc
finance.yahoo.com - May 11 at 9:37 AM
Here's Why Puma Biotechnology Inc. Is Sinking TodayHere's Why Puma Biotechnology Inc. Is Sinking Today
finance.yahoo.com - May 10 at 5:08 PM
Puma Biotechnology (PBYI) Releases Quarterly  Earnings Results, Beats Expectations By $0.61 EPSPuma Biotechnology (PBYI) Releases Quarterly Earnings Results, Beats Expectations By $0.61 EPS
www.americanbankingnews.com - May 10 at 4:46 PM
Puma Biotech (PBYI) Q1 Loss Narrows, Sales Miss, Stock DownPuma Biotech (PBYI) Q1 Loss Narrows, Sales Miss, Stock Down
www.zacks.com - May 10 at 9:07 AM
Puma Biotechnology (PBYI) Rating Lowered to Hold at Zacks Investment ResearchPuma Biotechnology (PBYI) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 9 at 6:51 PM
Puma Bio Q1 Nerlynx sales $36M; non-GAAP earnings up 103%Puma Bio Q1 Nerlynx sales $36M; non-GAAP earnings up 103%
seekingalpha.com - May 9 at 4:56 PM
Puma Biotechnology beats by $0.34, beats on revenuePuma Biotechnology beats by $0.34, beats on revenue
seekingalpha.com - May 9 at 4:56 PM
Puma Biotechnology Reports First Quarter 2018 Financial ResultsPuma Biotechnology Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 9 at 4:56 PM
Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2018Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2018
finance.yahoo.com - May 8 at 4:56 PM
Puma Biotechnology (PBYI) PT Set at $106.00 by Credit Suisse GroupPuma Biotechnology (PBYI) PT Set at $106.00 by Credit Suisse Group
www.americanbankingnews.com - May 8 at 2:28 PM
Puma Biotechnology (PBYI) Raised to Buy at Zacks Investment ResearchPuma Biotechnology (PBYI) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - May 7 at 1:13 PM
Puma Biotech (PBYI) to Report Q1 Earnings: What to Expect?Puma Biotech (PBYI) to Report Q1 Earnings: What to Expect?
www.zacks.com - May 7 at 8:53 AM
Puma Biotechnology (PBYI) Upgraded at ValuEnginePuma Biotechnology (PBYI) Upgraded at ValuEngine
www.americanbankingnews.com - May 2 at 10:54 PM
Puma Biotechnology (PBYI) Scheduled to Post Earnings on TuesdayPuma Biotechnology (PBYI) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - May 1 at 6:32 AM
Todays Research Reports on Trending Tickers: Neovasc and Puma BiotechnologyToday's Research Reports on Trending Tickers: Neovasc and Puma Biotechnology
finance.yahoo.com - April 30 at 9:04 AM
Puma Biotechnology (PBYI) Given a $106.00 Price Target at Credit Suisse GroupPuma Biotechnology (PBYI) Given a $106.00 Price Target at Credit Suisse Group
www.americanbankingnews.com - April 27 at 10:30 AM
Zacks: Brokerages Expect Puma Biotechnology Inc (PBYI) Will Announce Quarterly Sales of $69.32 MillionZacks: Brokerages Expect Puma Biotechnology Inc (PBYI) Will Announce Quarterly Sales of $69.32 Million
www.americanbankingnews.com - April 27 at 2:04 AM
Puma Biotechnology Inc (PBYI) Expected to Post Earnings of -$0.75 Per SharePuma Biotechnology Inc (PBYI) Expected to Post Earnings of -$0.75 Per Share
www.americanbankingnews.com - April 25 at 7:16 PM
Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial ResultsPuma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
finance.yahoo.com - April 25 at 4:59 PM
Puma Biotechnology Inc (PBYI) Receives Consensus Rating of "Hold" from AnalystsPuma Biotechnology Inc (PBYI) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 22 at 11:36 AM
Credit Suisse Group Reiterates "Outperform" Rating for Puma Biotechnology (PBYI)Credit Suisse Group Reiterates "Outperform" Rating for Puma Biotechnology (PBYI)
www.americanbankingnews.com - April 17 at 6:29 PM
Puma Biotechnologys (PBYI) Buy Rating Reaffirmed at CitigroupPuma Biotechnology's (PBYI) Buy Rating Reaffirmed at Citigroup
www.americanbankingnews.com - April 17 at 5:27 PM
BidaskClub Upgrades Puma Biotechnology (PBYI) to "Strong-Buy"BidaskClub Upgrades Puma Biotechnology (PBYI) to "Strong-Buy"
www.americanbankingnews.com - April 14 at 9:51 PM
The Market In 5 Minutes: Jobless Claims, Walmart-Flipkart, GE And MoreThe Market In 5 Minutes: Jobless Claims, Walmart-Flipkart, GE And More
www.benzinga.com - April 14 at 4:38 PM
Puma Biotechnology (PBYI) Stock Rating Reaffirmed by JPMorgan ChasePuma Biotechnology (PBYI) Stock Rating Reaffirmed by JPMorgan Chase
www.americanbankingnews.com - April 14 at 3:36 PM
Barclays Downgrades Puma Biotechnology (PBYI) to Equal WeightBarclays Downgrades Puma Biotechnology (PBYI) to Equal Weight
www.americanbankingnews.com - April 12 at 11:15 AM
JPMorgan Chase Analysts Give Puma Biotechnology (PBYI) a $105.00 Price TargetJPMorgan Chase Analysts Give Puma Biotechnology (PBYI) a $105.00 Price Target
www.americanbankingnews.com - April 11 at 1:19 PM
Puma Biotechnology (PBYI) Stock Rating Lowered by BidaskClubPuma Biotechnology (PBYI) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 10 at 8:55 PM
Puma Biotechnology (PBYI) Cut to "Hold" at BidaskClubPuma Biotechnology (PBYI) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - April 10 at 3:25 PM
Zacks: Analysts Anticipate Puma Biotechnology Inc (PBYI) Will Announce Quarterly Sales of $69.32 MillionZacks: Analysts Anticipate Puma Biotechnology Inc (PBYI) Will Announce Quarterly Sales of $69.32 Million
www.americanbankingnews.com - April 10 at 2:17 AM
Zacks: Analysts Anticipate Puma Biotechnology Inc (PBYI) to Announce -$0.75 EPSZacks: Analysts Anticipate Puma Biotechnology Inc (PBYI) to Announce -$0.75 EPS
www.americanbankingnews.com - April 8 at 9:14 PM
Puma Biotechnology (PBYI) Upgraded by BidaskClub to "Strong-Buy"Puma Biotechnology (PBYI) Upgraded by BidaskClub to "Strong-Buy"
www.americanbankingnews.com - April 8 at 9:07 AM
3 Things In Biotech, April 3: Alkermes Gets Into Trouble, Puma Gets Into Your Head, Myriad Gets Into Japan3 Things In Biotech, April 3: Alkermes Gets Into Trouble, Puma Gets Into Your Head, Myriad Gets Into Japan
seekingalpha.com - April 4 at 9:01 AM
Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin AmericaPuma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
finance.yahoo.com - April 3 at 9:11 AM
Puma's Shares Fall This Year Post a Solid 2017: Here's WhyPuma's Shares Fall This Year Post a Solid 2017: Here's Why
finance.yahoo.com - April 2 at 4:54 PM
NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination With Capecitabine or Paclitaxel as Treatment Options for Patients With Breast ...NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination With Capecitabine or Paclitaxel as Treatment Options for Patients With Breast ...
www.businesswire.com - April 2 at 9:26 AM
NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination With Capecitabine or Paclitaxel as Treatment Options for Patients With Breast Cancer Brain MetastasesNCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination With Capecitabine or Paclitaxel as Treatment Options for Patients With Breast Cancer Brain Metastases
finance.yahoo.com - April 2 at 9:26 AM
Puma Biotechnology (PBYI) Downgraded to Sell at ValuEnginePuma Biotechnology (PBYI) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - March 31 at 12:42 PM
Puma Biotechnology (PBYI) PT Set at $142.00 by Credit Suisse GroupPuma Biotechnology (PBYI) PT Set at $142.00 by Credit Suisse Group
www.americanbankingnews.com - March 28 at 3:48 PM
Puma Biotechnology Inc (PBYI) Receives Consensus Recommendation of "Buy" from AnalystsPuma Biotechnology Inc (PBYI) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 28 at 11:54 AM
3 Things In Biotech, March 26: A Focus On European Opinions3 Things In Biotech, March 26: A Focus On European Opinions
seekingalpha.com - March 27 at 9:18 AM
Commit To Purchase Puma Biotechnology At $50, Earn 11.9% Annualized Using Options - NasdaqCommit To Purchase Puma Biotechnology At $50, Earn 11.9% Annualized Using Options - Nasdaq
www.nasdaq.com - March 23 at 4:59 PM
Puma Biotechnology Inc (PBYI) Expected to Announce Earnings of -$0.75 Per SharePuma Biotechnology Inc (PBYI) Expected to Announce Earnings of -$0.75 Per Share
www.americanbankingnews.com - March 22 at 9:14 PM

SEC Filings

Puma Biotechnology (NASDAQ:PBYI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Puma Biotechnology (NASDAQ:PBYI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Puma Biotechnology (NASDAQ PBYI) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.